AbbVie (ABBV) said Monday its late-stage trial evaluating a subcutaneous induction treatment of Skyrizi in adults with active Crohn's disease met its co-primary efficacy endpoints at week 12.

The study showed 55% of patients receiving the drug achieved clinical remission and 44% reached an endoscopic response, compared with 30% and 14% for the placebo group, respectively, the company said.

The trial enrolled a predominantly treatment-resistant population and demonstrated a safety profile consistent with the medication's known risks, with serious adverse events occurring in 0.5% of treated patients versus 3.1% on placebo, AbbVie said.

The company also said the complete results will be shared at a later date.